PARIS, Nov. 6, 2013 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces, following the press release from November 4 th, that the acceleration of the clinical development program in ALS is in line with proof of efficacy experiments conducted in two different models that generated positive results of increased survival.
Acceleration Of Clinical Program In Amyotrophic Lateral Sclerosis (ALS) Confirms The Proof Of Efficacy Data Obtained In Animals
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.